We have read with great interest the recent article by PG Longo et al. 1 about different proliferative capacities of chronic lymphocytic leukemia B cells (CLL) from patients with progressive and stable disease. In their discussion Longo et al. refer to our work and conclude from their and our data that CpG oligodeoxynucleotide (ODN) may not be effective in patients with poor prognosis CLL that are most likely to require treatment.
Longo et al. emphasize in their introduction that a high leukemic cell birth rate has been found to correlate with disease progression, indicating that the difference in clinical course may, at least in part, be determined by the proliferative capacity of the CLL cells. In their publication Longo et al. demonstrate that the overall proliferative response to CpG ODN of mutated CLL cells (poor prognosis group) is higher than that of unmutated CLL cells (good prognosis group). 1 The authors cite our findings that CpG ODN induce apoptosis primarily in CLL samples with favorable but not with unfavorable cytogenetic aberrations. 2 While this conclusion is consistent with the measurement of the direct effect of CpG ODN on the viability of the CLL cells in vitro, we believe it reflects only one aspect of our findings and therefore would like to comment on the conclusions made by the authors.
In 2005, we published our research in this journal demonstrating that poor prognosis CLL cells have a higher spontaneous Figure 1 CpG ODN enhances immunogenicity of CLL cells regardless of their cytogenetic status. (a) B-CLL cells from 10 subjects with poor prognosis cytogenetics and 10 subjects with good prognosis cytogenetics were cultured for 4 days in the presence or absence of CpG ODN at 2.5 mg/ml. Expression of CD86 on days 0 and 4 was determined by FACS analysis. The average expression of this marker on B-CLL cells from different cytogenetic groups was compared. Error bars indicate s.e.m. (b) CD3 þ T cells from a buffy coat of a healthy blood donor were isolated by negative selection using magnetic beads and CFSE-labeled. 3 These T cells were cocultured for 5 days with CLL cells (CD19 þ cells) from seven subjects with different cytogenetics in the presence or absence of CpG ODN (2.5 mg/ml). The CLL-cell/T-cell ratio was 1:5. After 5 days, CFSE fluorescence of T cells was analyzed using flow cytometry and the percent of proliferating T cells was determined. All cocultures were run in duplicate, and standard deviation was o5% in each case. CFSE histograms of four different samples and controls with T cells only are shown. Percentages given indicate CFSE-low T cells, that is, T cells that have undergone proliferation. CFSE, carboxyfluorescein diacetate succinimidyl ester; FACS, Fluorescence Activated Cell Sorting. apoptosis rate in vitro compared to good prognosis CLL cells. This in vitro finding was consistent with the in vivo demonstration of higher LDH levels in patients with poor prognosis CLL. 3 Together, our results and those of Longo suggest that poor prognosis CLL is accompanied by a higher CLL cell turnover (that is, both proliferation and apoptosis). Given this finding, it is important to recognize that equating a tendency of poor prognosis CLL to proliferate in response to CpG ODN with a lack of potential clinical efficacy does not take sensitivity to apoptotic signals into account. It is the balance of proliferation and apoptosis that is most important.
We also evaluated how cytogenetics impacts on immunologic phenotype of the CLL cells. Poor prognosis CLL cells had significantly lower levels of immunologically relevant surface proteins (costimulatory, antigen-presenting and cell adhesion molecules) compared to CLL cells from the good prognosis group. 3 Functionally, CLL cells from the poor prognosis group induced less T-cell proliferation in mixed lymphocyte cultures than CLL cells from the good prognosis group. We previously published that CLL cells respond to CpG ODN by increasing the expression of these molecules. 4 Recently we have found that CpG ODN increases the expression of immunostimulatory molecules in all CLL samples irrespective of their cytogenetic status (Figure 1a) , and that allogeneic T-cell responses were stronger towards CLL cells pretreated with CpG ODN compared to untreated CLL cells irrespective of cytogenetics (Figure 1b) .
Taken together, these studies suggest that measurement of proliferation is only one aspect of the effect CpG ODN has on CLL cells. Induction of apoptosis and enhancement of an immunostimulatory phenotype may also be important. Our studies and those of Longo are consistent in that they demonstrate that CLL with poor prognosis genes, as measured by both cytogenetics and mutational status, are more likely to proliferate in response to CpG ODN than CLL with good prognosis genes. However, our studies, exploring the rate of turnover of CLL cells, and the effect of CpG ODN on the phenotype of the CLL cells, suggest CpG ODN could, indeed, have beneficial effects on CLL irrespective of genetic prognostic factors.
We are currently conducting a phase I trial of CpG ODN in CLL. This study is open to CLL subjects irrespective of cytogenetics or mutational status, and includes extensive laboratory correlation exploring phenotypic changes and evaluation of the tendency of the CLL cells to undergo apoptosis before and after therapy. While this phase I trial is not powered to compare poor to good prognosis CLL, it is an important first step in determining whether CpG ODN is likely to be of use in subjects with CLL, and if so, which patients are most likely to be benefited. B Jahrsdorfer 1 , S Blackwell 2 and G Weiner
In our recent article, we addressed the issue of the different proliferative capacity of CLL B-cells from patients with progressive disease and poor prognostic features (V H unmutated) and patients with stable disease and good prognostic features (V H mutated). 1 During this study, we also observed that CpG ODN stimulation leads to cell cycle arrest and induction of apoptosis in CLL B cells from most cases with stable disease and mutated V H genes. In contrast, CpG ODN stimulation either had no effect on leukemic cell survival or resulted in decreased spontaneous apoptosis in the majority of cases with progressive disease and unmutated V H genes. These data were obtained by annexin V/propidium iodide analysis of CLL B-cells cultured for 48 h with or without CpG ODN. The results were presented in our paper and are shown again in Figure 1a . Thus, our conclusion that CpG ODN may not be an effective treatment in a subset of poor prognosis patients was based on direct assessment of apoptotic sensitivity, and was not based on the 'tendency of poor prognosis CLL to proliferate in response to CpG ODN', as suggested by Jahrsdorfer et al.
2 in their letter. Sensitivity to CpG ODN-induced apoptosis was additionally investigated in selected cases by analysis of PARP cleavage. These data are now presented in Figure 1b and confirm that certain CLL cases, mainly those with progressive disease and unmutated V H genes, are resistant to CpG ODN-induced apoptosis. Together, these observations lead us to suggest that CpG ODN may not be effective in a subset of poor prognosis patients, unless pathways that regulate pro-survival signaling are not blocked simultaneously. However, we agree with Jahrsdorfer et al. that the absence of a direct apoptotic effect in vitro does not exclude the possibility that CpG ODN may still be beneficial
